U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H22Cl2N4
Molecular Weight 473.396
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of Clofazimine

SMILES

CC(C)\N=C1/C=C2N(C3=CC=C(Cl)C=C3)C4=C(C=CC=C4)N=C2C=C1NC5=CC=C(Cl)C=C5

InChI

InChIKey=WDQPAMHFFCXSNU-BGABXYSRSA-N
InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24+

HIDE SMILES / InChI
Molecular Formula C27H22Cl2N4
Molecular Weight 473.396
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68002991

Clofazimine (Lamprene®) is a fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine (Lamprene®) exerts a slow bactericidal effect on Mycobacterium leprae (Hansen’s bacillus). It inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. It also exerts anti-inflammatory properties in controlling erythema nodosum leprosum reactions. However, its precise mechanisms of action are unknown.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Clofazimine crosses the placenta and, albeit in very small amounts, the blood-brain barrier.

Originator

Approval Year

1986
107
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
LAMPRENE

Approved Use

Lamprene is indicated in the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. Lamprene has not been demonstrated to be effective in the treatment of other leprosy-associated inflammatory reactions.

Launch Date

1986
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.5 mg/L
REVIEW
https://pubmed.ncbi.nlm.nih.gov/2656045/
300 mg 3 times / week multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
0.7 mg/L
REVIEW
https://pubmed.ncbi.nlm.nih.gov/2656045/
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1 mg/L
REVIEW
https://pubmed.ncbi.nlm.nih.gov/2656045/
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1.4 mg/L
REVIEW
https://pubmed.ncbi.nlm.nih.gov/2656045/
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
861 pmol/g
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3559339/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
604 pmol/g
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3559339/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
469 pmol/g
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3559339/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33900 pmol × h/g
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3559339/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
29100 pmol × h/g
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3559339/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
18000 pmol × h/g
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3559339/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.6 day
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/3559339/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOFAZIMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
200 mg single, oral
Highest studied dose
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/3559339
unhealthy, 30-60
Health Status: unhealthy
Age Group: 30-60
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/3559339
Sources:
https://pubmed.ncbi.nlm.nih.gov/3559339
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Other AEs: Gastrointestinal obstruction, Gastrointestinal bleeding...
Other AEs:
Gastrointestinal obstruction (grade 3-5)
Gastrointestinal bleeding (grade 3-5)
Splenic infarction (grade 3-5)
QT interval prolonged
Torsade de pointes
Discoloration urine
Depression
Suicidal ideation
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Other AEs: Skin discoloration...
Other AEs:
Skin discoloration (75-100)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Other AEs: Ichthyosis, Dry skin...
Other AEs:
Ichthyosis
Dry skin
Pruritus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
200 mg single, oral
Recommended
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Depression
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Discoloration urine
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
QT interval prolonged
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Suicidal ideation
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Torsade de pointes
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Gastrointestinal bleeding grade 3-5
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Gastrointestinal obstruction grade 3-5
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Splenic infarction grade 3-5
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Skin discoloration 75-100
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Dry skin
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Ichthyosis
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Pruritus
100 mg 1 times / day steady, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inducer
1087

inhibitor
2252
inhibitor
2507

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741

BCRP
910

MRP1
116

BSEP
550
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1932
 strong [IC50 1.8 uM]
BCRP
985
 strong [IC50 3.2 uM]
MRP1
232
 strong [IC50 6.8 uM]
CYP3A4
2633
 yes [IC50 0.275 uM]
no (co-administration study)
Comment: No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with clofazimine: dapsone or rifampicin
Page: 4.0
BSEP
554
 yes [IC50 2.3 uM]
CYP2D6
2546
 yes [IC50 4.54 uM]
no (co-administration study)
Comment: No clinically significant differences in the pharmacokinetics of the following drugs were observed when used concomitantly with clofazimine: dapsone or rifampicin
Page: 4.0
CYP3A4
2633
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:3749
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3749
MolPort
MolPort-042-621-745
https://www.molport.com/shop/molecule-link/MolPort-042-621-745
ZINC
ZINC000253916263
http://zinc15.docking.org/substances/ZINC000253916263
PubMed

PubMed

TitleDatePubMed
10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
2004-09-09
Intra-abdominal, crystal-storing histiocytosis due to clofazimine in a patient with lepromatous leprosy and concurrent carcinoma of the colon.
2004-06
Shiny red-brown papules in a 21-year-old man. Histoid leprosy.
2004-06
Antimicrobial activity of clofazimine is not dependent on mycobacterial C-type phospholipases.
2004-06
Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh.
2004-05
Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol.
2004-04-15
Human case of lobomycosis.
2004-04
Relapses in multibacillary patients treated with multi-drug therapy until smear negativity: findings after twenty years.
2004-03
Erythema dyschromicum perstans: response to dapsone therapy.
2004-03
Anti-staphylococcal activity and mode of action of clofazimine.
2004-03
Cheilitis granulomatosa of Melkersson-Rosenthal syndrome: treatment with intralesional corticosteroid injections.
2004-02-26
Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses.
2004-02-20
Morbihan's disease: treatment with CO2 laser blepharoplasty.
2004-02
A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents.
2004-02
[Guideline for the treatment of leprosy by new quinolones].
2004-02
Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
2004-02
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method.
2004-01
Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients.
2004
Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
2003-12
Chronic recurrent ENL, steroid dependent: long-term treatment with high dose clofazimine.
2003-12
Invasive Mycobacterium marinum infections.
2003-11
Lepromatous leprosy and reversal reaction in a Micronesian immigrant.
2003-11
Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.
2003-10
Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy.
2003-09
Determination of clofazimine in leprosy patients by high-performance liquid chromatography.
2003-09
Along these lines...
2003-09
Dapsone induced cholangitis as a part of dapsone syndrome: a case report.
2003-08-11
[Leprosy in Brazil].
2003-08-09
[A case of lepromatous type Hansen's disease].
2003-08
[A case of Hansen's disease seen in an Indonesian resident, and tracing of the patient after coming back to Indonesia].
2003-08
Efficacy of clofazimine-modified cyclodextrin against Mycobacterium avium complex in human macrophages.
2003-07-09
Leprosy in a Mexican immigrant.
2003-07
Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
2003-06
Disseminated Mycobacterium chelonae cutaneous infection: recalcitrant to combined antibiotic therapy.
2003-06
Pulsed corticosteroid therapy in patients with chronic recurrent ENL: a pilot study.
2003-04-24
Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
2003-03-11
[Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlândia].
2003-03-08
A retrospective study regarding the treatment of lupoid onychodystrophy in 30 dogs and literature review.
2003-03-06
Short report: Treatment failure in Hansen's disease.
2003-02
[Histoid leprosy with erythema nodosum leprosum].
2003
[Hansen's disease in the laboratory].
2003
Probing cell chemistry with time-of-flight secondary ion mass spectrometry: development and exploitation of instrumentation for studies of frozen-hydrated biological material.
2003
Less common methods to treat acne.
2003
Leprosy.
2002-12
[Pyoderma gangrenosum--positive effect of cyclosporin A therapy ].
2002-10
Hansen's disease mimicking palmoplantar keratoderma.
2002-09
Advances in the diagnosis and treatment of leprosy.
2002-07-22
[Systematic search for parasites among leprosy patients in Mali].
2002
Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs?
1992-12
In-vivo activity of streptomycin and clofazimine against established infections of Mycobacterium avium complex in beige mice.
1992-12
Patents

Patents

US2948726
1

Sample Use Guides

In Vivo Use Guide
Lamprene® should be given at a dosage of 100 mg daily in combination with one or more other antileprosy drugs for 3 years, followed by monotherapy with 100 mg of Lamprene® daily. It should be taken with meals.
Route of Administration: Oral
In Vitro Use Guide
The following in vitro data are available, but their clinical significance is unknown. Lamprene® has been shown in vitro to inhibit M. avium and M. bovis at concentrations of approximately 0.1-1.0 ug/mL. The MIC for M. avium-intracellulare isolated from patients with acquired immunodeficiency syndrome (AIDS) ranged from 1.0 to 5.0 ug/mL.
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:40:31 GMT 2025
Edited
by admin
on Mon Mar 31 23:40:31 GMT 2025
Record UNII
D959AE5USF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Clofazimine
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
LAMPRENE
Preferred Name English
G-30320
Code English
Clofazimine [WHO-IP]
Common Name English
Clofazimine [MI]
Common Name English
Clofazimine [USP IMPURITY]
Common Name English
Clofazimine [USP MONOGRAPH]
Common Name English
N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine
Systematic Name English
Clofazimine [EP MONOGRAPH]
Common Name English
Clofazimine [WHO-DD]
Common Name English
2-Phenazinamine, N,5-bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-
Systematic Name English
CLOFAZIMINUM [WHO-IP LATIN]
Common Name English
clofazimine [INN]
Common Name English
CHLOFAZIMINE
Common Name English
Clofazimine [ORANGE BOOK]
Common Name English
3-(P-CHLOROANILINO)-10-(P-CHLOROPHENYL)-2,10-DIHYDRO-2-(ISOPROPYLIMINO)PHENAZINE
Common Name English
Clofazimine [USAN]
Common Name English
G30320
Code English
COLFAZIMINE [VANDF]
Common Name English
Clofazimine [VANDF]
Common Name English
Clofazimine [USP-RS]
Common Name English
Clofazimine [JAN]
Common Name English
NSC-141046
Code English
Clofazimine [MART.]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 770820
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
WHO-ATC J04BA01
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
FDA ORPHAN DRUG 2684
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
NCI_THESAURUS C258
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
WHO-VATC QJ04BA01
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
LIVERTOX NBK548658
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
FDA ORPHAN DRUG 646318
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
NDF-RT N0000175483
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
FDA ORPHAN DRUG 338811
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
FDA ORPHAN DRUG 436314
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 6.2.3
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
Code System Code Type Description
RXCUI
2592
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY RxNorm
FDA UNII
D959AE5USF
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
INN
2248
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
CAS
2030-63-9
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
SMS_ID
100000092385
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
NSC
141046
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
DRUG BANK
DB00845
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
RS_ITEM_NUM
1138904
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
EVMPD
SUB06694MIG
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
EPA CompTox
DTXSID7022839
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CLOFAZIMINE
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY Description: A reddish brown, fine powder; odourless or almost odourless.Solubility: Practically insoluble in water; slightly soluble in ethanol (~750 g/l) TS and in ether R.Category: Antileprosy drug.Storage: Clofazimine should be kept in a well-closed container.Additional information: Clofazimine melts at about 217 ?C.
NCI_THESAURUS
C47456
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
MESH
D002991
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
WIKIPEDIA
CLOFAZIMINE
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
LACTMED
Clofazimine
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
ECHA (EC/EINECS)
217-980-2
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
MERCK INDEX
m3637
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY Merck Index
DRUG CENTRAL
692
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
CHEBI
3749
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
ChEMBL
CHEMBL1292
Created by admin on Mon Mar 31 23:40:31 GMT 2025 , Edited by admin on Mon Mar 31 23:40:31 GMT 2025
PRIMARY
Related Record Type Details
BSEP
TRANSPORTER -> INHIBITOR
Structure of Clofazimine nitrate
SALT/SOLVATE -> PARENT
MYCOBACTERIUM LEPRAE
TARGET ORGANISM->INHIBITOR
Related Record Type Details
Structure of 1-HYDROXY-CLOFAZIMINE
METABOLITE -> PARENT
Structure of CLOFAZIMINE HYDROGEN-SULFATE
METABOLITE -> PARENT
Structure of PHENOL, 4-((5-(4-CHLOROPHENYL)-3,5-DIHYDRO-3-((1-METHYLETHYL)IMINO)-2-PHENAZINYL)AMINO)-
METABOLITE -> PARENT
Related Record Type Details
Structure of N,5-BIS(4-CHLOROPHENYL)-3,5-DIHYDRO-3-IMINO-2-PHENAZINAMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 5-(4-CHLOROPHENYL)-3-(ISOPROPYLIMINO)-N-PHENYL-3,5-DIHYDROPHENAZIN-2-AMINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of Clofazimine
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966